RPB5‐Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for KEAP1 Binding

Zheng‐Hua Wan, Tian‐Yi Jiang, Yuan‐Yuan Shi, Yu‐Fei Pan, Yun‐Kai Lin, Yun‐Han Ma, Chun Yang, Xiao‐Fan Feng, Li‐Feng Huang, Xiao‐Ni Kong, Zhi‐Wen Ding, Ye‐Xiong Tan, Li‐Wei Dong, Hong‐Yang Wang – 21 September 2019

Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus–Viremic Livers

Rafal D. Mazur, David S. Goldberg – 20 September 2019 – The high efficacy of current hepatitis C virus (HCV) therapy and increased numbers of HCV‐infected deceased donors have changed the paradigm of HCV in liver transplantation (LT). Modeling studies have been performed to evaluate the optimal timing of HCV treatment (before versus after LT) in HCV‐infected patients and to assess the cost‐effectiveness of transplanting HCV‐infected livers into HCV− patients.

Subscribe to